Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity
Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune
The FDA said Hutchmed's medicine can have special protection. This means the company gets 7 years where no copies can compete.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.